比较普通PTFE与肝素结合PTFE膝下旁路移植的随机对照试验(REPLACE):设计与方案
REPLACE试验为法国20中心单盲随机对照试验,纳入无合适自体静脉的严重下肢缺血患者,比较肝素结合PTFE与普通PTFE膝下旁路移植。主要终点为1年多普勒超声通畅率,计划随机228例(每组114例),并评估安全性、生活质量和成本效用。
要点
- 严重下肢缺血无合适自体静脉时,肝素结合PTFE可能优于普通PTFE,但需前瞻性验证。
- 主要终点为1年 duplex 超声评估的通畅率,任何为开放或预防移植物闭塞的干预均视为通畅丧失。
- 样本量基于普通PTFE 1年通畅率53%、肝素结合PTFE 74%的假设,计划随机228例。
核心结论
- REPLACE试验是首个设计用于确定肝素结合PTFE移植物在严重下肢缺血膝下旁路手术中是否优于普通PTFE移植物的随机对照试验。
研究设计与样本
- 单盲随机对照试验,在法国20个中心进行。
- 纳入评估为无合适自体静脉用于严重下肢缺血旁路移植的患者,随机接受肝素结合PTFE或普通PTFE移植物。
- 基于文献复习假设普通ePTFE组1年通畅率53%、肝素结合PTFE组74%,取α=0.05、1:1随机,需176例(每组88例)以获得约80%把握度拒绝零假设。
- 假设1年脱落10%、死亡率20%,计划随机228例(每组114例)。
主要发现
- 主要结局变量为通过 duplex 彩色血流扫描评估的1年通畅率。
- 1年前任何为开放或预防移植物闭塞的干预将被归类为通畅丧失。
- 技术成功、死亡、并发症、主要不良心脑血管和肢体事件、住院时间及生活质量将作为次要结局变量记录和分析。
- 将基于法国健康保险系统标准费率进行成本效用和成本效果分析。
关键数值与推荐
- 预期1年通畅率:普通ePTFE组53%,肝素结合PTFE组74%。
- 显著性水平α=0.05,随机比例1:1,共需176例(每组88例)以获得约80%把握度。
- 假设1年脱落10%和死亡率20%,计划随机228例(每组114例)。
- 主要终点为1年 duplex 超声评估的通畅率,任何为开放或预防移植物闭塞的干预均视为通畅丧失。
临床怎么用
- 为严重下肢缺血无合适自体静脉需膝下旁路移植的患者,提供肝素结合PTFE与普通PTFE疗效比较的前瞻性随机证据。
- 试验结果将帮助临床决策是否优先选用肝素结合PTFE移植物以改善1年通畅率。
- 同时评估安全性、生活质量和成本效果,为卫生经济学评价提供依据。
局限性
- 单盲设计,患者可能知晓移植物类型。
- 样本量基于文献假设的通畅率,实际事件率可能影响把握度。
- 1年脱落率10%和死亡率20%的假设可能影响最终分析样本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although autogenous venous grafts are preferable for below-the-knee bypass surgery in patients with critical limb ischemia, some 20% of patients will have no suitable vein for grafting, compelling a resort to artificial graft materials. Retrospective subgroup analyses within published studies comparing heparin-bonded polytetrafluoroethylene (PTFE) with crude PFTE graft in below-the-knee bypass suggest that heparin-bonded graft offers superior long-term patency rates, but this has not been prospectively verified in patients with critical limb ischemia. METHODS: A single-blind randomized controlled trial in 20 French centers has been designed. Patients assessed as having no suitable autologous vein for bypass grafting for critical lower limb ischemia will be randomized to receive either a heparin-bonded PTFE graft or a crude PTFE graft. A literature review suggested expected 1-year patency rates of 53% for the crude ePTFE arm and 74% for the heparin-bonded PTFE arm. On analyzing 1-year patency rate as a binary variable, for a significance level α = 0.05 and a randomization ratio of 1:1, a total of 176 patients (88 in each arm) will be required to obtain approximately 80% power to reject the null hypothesis. Assuming 10% dropout at 1 year and 20% mortality, 228 patients will be randomized (114 patients in each arm). RESULTS: The primary outcome variable will be patency at 1 year assessed by duplex ultrasound color-flow scan. Any intervention to open up or prevent a graft occlusion before 1 year will be classified as loss of patency. Technical success, deaths, complications, major adverse cardiovascular and limb events, length of hospitalization, and quality of life will also be recorded and analyzed as secondary outcome variables. Cost-utility and cost-effectiveness analyses based on standard tariffs in the French health insurance system will be performed. CONCLUSIONS: The REPLACE trial is the first randomized controlled trial designed to determine if heparin-bonded PTFE graft is superior to crude PTFE graft in below-the-knee bypass surgery for critical limb ischemia.
引用
- Gouëffic Y, Favre JP, Steinmetz E, et al. A Randomized Controlled Trial Comparing Crude Versus Heparin-Bonded PTFE Graft in Below the Knee Bypass Surgery for Critical Limb Ischemia (REPLACE Trial): Design and Protocol. Ann Vasc Surg. 2019. PMID: 30769063. doi:10.1016/j.avsg.2018.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。